+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Optic Nerve Disorders Drug Development Pipeline Review, 2018

  • ID: 4663544
  • Report
  • 149 Pages
  • GBI Research
1 of 4

FEATURED COMPANIES

  • AC Immune SA
  • Bionure Farma SL
  • Fortify Therapeutics Inc
  • Inspyr Therapeutics Inc
  • Mitotech SA
  • Oncolys BioPharma Inc
  • MORE

Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. There are 10 products in development for this indication.

Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye. There are 13 products in development for this indication.

LHON is an inherited form of vision loss. This condition usually begins in a person’s teens or twenties. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. There are 16 products in development for this indication.

Optic neuritis refers to inflammation of the optic nerve. Symptoms include pain, vision loss, dyschromatopsia (impaired ability to perceive colors) and flashing lights. There are 12 products in development for this indication.

Molecular targets acted on by products in development for optic nerve disorders include kinases, growth factors and cannabinoid receptors. Companies operating in this pipeline space include NicOx SA Regeneron Pharmaceuticals and Amgen

This report “Optic Nerve Disorders Drug Development Pipeline Review, 2018” provides an overview of the pipeline landscape for disorders of the optic nerve, the bundle of nerve fibers that transmits visual information from the eye to the brain. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for optic neuropathy, glaucoma, Leber’s hereditary optic neuropathy (LHON) and optic neuritis, and features dormant and discontinued products.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AC Immune SA
  • Bionure Farma SL
  • Fortify Therapeutics Inc
  • Inspyr Therapeutics Inc
  • Mitotech SA
  • Oncolys BioPharma Inc
  • MORE

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Optic Nerve Disorders Report Coverage
2.2 Optic Neuropathy - Overview
2.3 Glaucoma - Overview
2.4 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Overview
2.5 Optic Neuritis - Overview

3 Therapeutics Development
3.1 Optic Neuropathy
3.2 Glaucoma
3.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
3.4 Optic Neuritis

4 Therapeutics Assessment
4.1 Optic Neuropathy
4.2 Glaucoma
4.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
4.4 Optic Neuritis

5 Companies Involved in Therapeutics Development
5.1 Optic Neuropathy
5.2 Glaucoma
5.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
5.4 Optic Neuritis

6 Dormant Projects
6.1 Optic Neuropathy
6.2 Glaucoma
6.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
6.4 Optic Neuritis

7 Discontinued Products
7.1 Optic Neuropathy
7.2 Glaucoma
7.3 Optic Neuritis

8 Product Development Milestones
8.1 Optic Neuropathy
8.2 Glaucoma
8.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
8.4 Optic Neuritis

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer

List of Tables
Table 1: Number of Products under Development for Optic Neuropathy
Table 2: Number of Products under Development by Companies, Optic Neuropathy
Table 3: Number of Products under Development by Universities/Institutes, Optic Neuropathy
Table 4: Products under Development by Companies, Optic Neuropathy
Table 5: Products under Development by Universities/Institutes, Optic Neuropathy
Table 6: Number of Products under Development for Glaucoma
Table 7: Number of Products under Development by Companies, Glaucoma
Table 8: Number of Products under Development by Universities/Institutes, Glaucoma
Table 9: Products under Development by Companies, Glaucoma
Table 10: Products under Development by Universities/Institutes, Glaucoma
Table 11: Number of Products under Development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 12: Number of Products under Development by Companies, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 13: Number of Products under Development by Universities/Institutes, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 14: Products under Development by Companies, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 15: Products under Development by Universities/Institutes, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 16: Number of Products under Development for Optic Neuritis
Table 17: Number of Products under Development by Companies, Optic Neuritis
Table 18: Number of Products under Development by Universities/Institutes, Optic Neuritis
Table 19: Products under Development by Companies, Optic Neuritis
Table 20: Products under Development by Universities/Institutes, Optic Neuritis
Table 21: Number of Products by Stage and Target, Optic Neuropathy
Table 22: Number of Products by Stage and Mechanism of Action, Optic Neuropathy
Table 23: Number of Products by Stage and Route of Administration, Optic Neuropathy
Table 24: Number of Products by Stage and Molecule Type, Optic Neuropathy
Table 25: Number of Products by Stage and Target, Glaucoma
Table 26: Number of Products by Stage and Mechanism of Action, Glaucoma
Table 27: Number of Products by Stage and Route of Administration, Glaucoma
Table 28: Number of Products by Stage and Molecule Type, Glaucoma
Table 29: Number of Products by Stage and Target, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 30: Number of Products by Stage and Mechanism of Action, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 31: Number of Products by Stage and Route of Administration, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 32: Number of Products by Stage and Molecule Type, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 33: Number of Products by Stage and Target, Optic Neuritis
Table 34: Number of Products by Stage and Mechanism of Action, Optic Neuritis
Table 35: Number of Products by Stage and Route of Administration, Optic Neuritis
Table 36: Number of Products by Stage and Molecule Type, Optic Neuritis
Table 37: Optic Neuropathy - Pipeline by Amgen Inc, H2 2018
Table 38: Optic Neuropathy - Pipeline by Ironwood Pharmaceuticals Inc, H2 2018
Table 39: Optic Neuropathy - Pipeline by Quark Pharmaceuticals Inc, H2 2018
Table 40: Optic Neuropathy - Pipeline by Regenera Pharma Ltd, H2 2018
Table 41: Optic Neuropathy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Table 42: Glaucoma - Pipeline by AC Immune SA, H2 2018
Table 43: Glaucoma - Pipeline by Aerie Pharmaceuticals Inc, H2 2018
Table 44: Glaucoma - Pipeline by Allergan Plc, H2 2018
Table 45: Glaucoma - Pipeline by Altacor Ltd, H2 2018
Table 46: Glaucoma - Pipeline by Amarantus Bioscience Holdings Inc, H2 2018
Table 47: Glaucoma - Pipeline by Amgen Inc, H2 2018
Table 48: Glaucoma - Pipeline by Annexon Inc, H2 2018
Table 49: Glaucoma - Pipeline by Astellas Pharma Inc, H2 2018
Table 50: Glaucoma - Pipeline by Bial - Portela & Ca SA, H2 2018
Table 51: Glaucoma - Pipeline by BioAxone BioSciences Inc, H2 2018
Table 52: Glaucoma - Pipeline by Can-Fite BioPharma Ltd, H2 2018
Table 53: Glaucoma - Pipeline by Cellix Bio Pvt Ltd, H2 2018
Table 54: Glaucoma - Pipeline by Certa Therapeutics Pty Ltd, H2 2018
Table 55: Glaucoma - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018
Table 56: Glaucoma - Pipeline by D. Western Therapeutics Institute Inc, H2 2018

List of Figures
Figure 1: Number of Products under Development for Optic Neuropathy
Figure 2: Number of Products under Development by Companies, Optic Neuropathy
Figure 3: Number of Products under Development for Glaucoma
Figure 4: Number of Products under Development by Companies, Glaucoma
Figure 5: Number of Products under Development by Universities/Institutes, Glaucoma
Figure 6: Number of Products under Development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Figure 7: Number of Products under Development by Companies, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Figure 8: Number of Products under Development for Optic Neuritis
Figure 9: Number of Products under Development by Companies, Optic Neuritis
Figure 10: Number of Products by Top 10 Targets, Optic Neuropathy
Figure 11: Number of Products by Stage and Top 10 Targets, Optic Neuropathy
Figure 12: Number of Products by Top 10 Mechanism of Actions, Optic Neuropathy
Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Optic Neuropathy
Figure 14: Number of Products by Routes of Administration, Optic Neuropathy
Figure 15: Number of Products by Stage and Routes of Administration, Optic Neuropathy
Figure 16: Number of Products by Molecule Types, Optic Neuropathy
Figure 17: Number of Products by Stage and Molecule Types, Optic Neuropathy
Figure 18: Number of Products by Top 10 Targets, Glaucoma
Figure 19: Number of Products by Stage and Top 10 Targets, Glaucoma
Figure 20: Number of Products by Top 10 Mechanism of Actions, Glaucoma
Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Glaucoma
Figure 22: Number of Products by Routes of Administration, Glaucoma
Figure 23: Number of Products by Stage and Routes of Administration, Glaucoma
Figure 24: Number of Products by Top 10 Molecule Types, Glaucoma
Figure 25: Number of Products by Stage and Top 10 Molecule Types, Glaucoma
Figure 26: Number of Products by Targets, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Figure 27: Number of Products by Stage and Targets, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Figure 28: Number of Products by Mechanism of Actions, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Figure 29: Number of Products by Stage and Mechanism of Actions, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Figure 30: Number of Products by Routes of Administration, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Figure 31: Number of Products by Stage and Routes of Administration, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Figure 32: Number of Products by Molecule Types, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Figure 33: Number of Products by Stage and Molecule Types, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Figure 34: Number of Products by Targets, Optic Neuritis
Figure 35: Number of Products by Stage and Targets, Optic Neuritis
Figure 36: Number of Products by Mechanism of Actions, Optic Neuritis
Figure 37: Number of Products by Stage and Mechanism of Actions, Optic Neuritis
Figure 38: Number of Products by Routes of Administration, Optic Neuritis
Figure 39: Number of Products by Stage and Routes of Administration, Optic Neuritis
Figure 40: Number of Products by Molecule Types, Optic Neuritis
Figure 41: Number of Products by Stage and Molecule Types, Optic Neuritis

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AC Immune SA
  • Aerie Pharmaceuticals Inc
  • Alkeus Pharmaceuticals Inc
  • Allergan Plc
  • Altacor Ltd
  • Amarantus Bioscience Holdings Inc
  • Amgen Inc
  • Annexon Inc
  • Astellas Pharma Inc
  • Bactevo Ltd
  • Bial - Portela & Ca SA
  • BioAxone BioSciences Inc
  • Bionure Farma SL
  • Biovista Inc
  • Can-Fite BioPharma Ltd
  • Cellix Bio Pvt Ltd
  • Certa Therapeutics Pty Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • Coma
  • Commence Bio Inc
  • D. Western Therapeutics Institute Inc
  • Disarm Therapeutics Inc
  • Dompe Farmaceutici SpA
  • Elsalys Biotech SA
  • EyePoint Pharmaceuticals Inc
  • Eyevensys SAS
  • Fortify Therapeutics Inc
  • Fortress Biotech Inc
  • GenSight Biologics SA
  • Gene Signal International SA
  • Glaukos Corp
  • Graybug Vision Inc
  • Han Wha Pharma Co Ltd
  • Handok Inc
  • HitGen LTD
  • ID Pharma Co Ltd
  • InMed Pharmaceuticals Inc
  • Inspyr Therapeutics Inc
  • Ironwood Pharmaceuticals Inc
  • Isarna Therapeutics GmbH
  • Ixchel Pharma LLC
  • Khondrion BV
  • Kowa Co Ltd
  • Kukje Pharmaceutical Industry Co Ltd
  • Laboratorios SALVAT SA
  • Laboratorios Sophia SA de CV
  • Lee's Pharmaceutical Holdings Ltd
  • Lipocure Ltd
  • Meta-IQ ApS
  • MimeTech Srl
  • Mitobridge Inc
  • Mitochon Pharmaceuticals Inc
  • Mitotech SA
  • Nemus Bioscience Inc
  • Neurim Pharmaceuticals Ltd
  • Neuritis
  • NicOx SA
  • NoNO Inc
  • Novaliq GmbH
  • Novartis AG
  • Ocular Therapeutix Inc
  • Oculis ehf
  • Ohr Pharmaceutical Inc
  • Oncolys BioPharma Inc
  • Pivot Pharmaceuticals Inc
  • Profarma
  • Q BioMed Inc
  • ReNetX Bio
  • Regenera Pharma Ltd
  • Santen Pharmaceutical Co Ltd
  • Santhera Pharmaceuticals Holding AG
  • Senju Pharmaceutical Co Ltd
  • Shire Plc
  • Spark Therapeutics Inc
  • Stealth BioTherapeutics Inc
  • Sun Pharma Advanced Research Company Ltd
  • Sylentis SAU
  • Taejoon Pharm Co Ltd
  • Teijin Pharma Ltd
  • TikoMed AB
  • Unity Biotechnology Inc
Note: Product cover images may vary from those shown
Adroll
adroll